AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst Ratings Changes

A number of research analysts have issued reports on ABBV shares. Daiwa Capital Markets cut shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 target price for the company. in a report on Friday, May 6th. BMO Capital Markets lifted their price target on AbbVie from $161.00 to $174.00 and gave the company an "outperform" rating in a report on Monday, April 25th. Morgan Stanley cut their target price on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a research note on Monday, August 1st. Barclays decreased their price objective on shares of AbbVie to $160.00 in a report on Tuesday. Finally, SVB Leerink started coverage on shares of AbbVie in a report on Monday, May 23rd. They set an "underperform" rating and a $140.00 target price for the company. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $159.63.

AbbVie Trading Up 0.5 %

AbbVie stock opened at $140.94 on Thursday. AbbVie has a 12 month low of $105.56 and a 12 month high of $175.91. The stock's 50 day simple moving average is $147.18 and its two-hundred day simple moving average is $150.27. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. The firm has a market cap of $249.20 billion, a PE ratio of 19.96, a P/E/G ratio of 3.88 and a beta of 0.70.

AbbVie (NYSE:ABBV - Get Rating) last issued its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.42 by $0.09. The firm had revenue of $14.58 billion for the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.11 EPS. Analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be paid a dividend of $1.41 per share. This represents a $5.64 annualized dividend and a yield of 4.00%. The ex-dividend date is Thursday, July 14th. AbbVie's dividend payout ratio (DPR) is currently 79.89%.

Insider Buying and Selling

In related news, Vice Chairman Michael Severino sold 100,000 shares of the firm's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the completion of the sale, the insider now directly owns 152,103 shares of the company's stock, valued at approximately $23,492,308.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Vice Chairman Michael Severino sold 100,000 shares of the business's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the sale, the insider now directly owns 152,103 shares in the company, valued at $23,492,308.35. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Henry O. Gosebruch sold 83,960 shares of AbbVie stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now owns 16,623 shares of the company's stock, valued at approximately $2,576,565. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 263,761 shares of company stock worth $40,500,771. Insiders own 0.08% of the company's stock.